Company Overview - InnoCare aims to become a global biopharmaceutical leader, focusing on oncology and autoimmune diseases[6, 7, 8] - The company has raised a total of $134 billion USD since its founding in 2015[11] - InnoCare has a fully-integrated drug innovation platform with 13 clinical products in the pipeline and 2 marketed products[13] Orelabrutinib (BTKi) - Orelabrutinib demonstrates ~100% BTK occupation at 50 mg QD and above, with an improved safety profile[23] - Orelabrutinib has shown an 83% overall response rate (ORR) in r/r MCL patients and a 589% ORR in r/r MZL patients[34] - A Phase III registrational trial for Orelabrutinib is ongoing in China for SLE[52] ICP-332 (TYK2 Inhibitor) - ICP-332, at 80mg QD, achieved a 782% reduction from baseline in EASI score in Atopic Dermatitis (AD) patients[75] - 88% of patients achieved EASI 50 and 72% achieved EASI 75 at Week 4 with ICP-332 treatment[75] - Global AD market is expected to reach $222 billion USD by 2028[71] Portfolio Expansion - Tafasitamab BLA submission in China is planned for 2024Q2, targeting 160,000 new DLBCL patients globally per annum[46] - ICP-248 (BCL-2 inhibitor) showed 100% efficacy (6 out of 6 patients) in early clinical results[41] - InnoCare plans to submit an NDA for 1L CLL/SLL in China and r/r MCL in the USA for Orelabrutinib in the second half of 2024[102]
诺诚健华(09969) - 2024 FY - 电话会议演示